CN101375983B - 一种用于治疗痛经的中药组合物及其制备方法 - Google Patents
一种用于治疗痛经的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN101375983B CN101375983B CN200810151194XA CN200810151194A CN101375983B CN 101375983 B CN101375983 B CN 101375983B CN 200810151194X A CN200810151194X A CN 200810151194XA CN 200810151194 A CN200810151194 A CN 200810151194A CN 101375983 B CN101375983 B CN 101375983B
- Authority
- CN
- China
- Prior art keywords
- extraction
- rhizoma chuanxiong
- rhizoma
- dysmenorrhea
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 206010013935 Dysmenorrhoea Diseases 0.000 title claims abstract description 46
- 208000005171 Dysmenorrhea Diseases 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 238000000605 extraction Methods 0.000 claims abstract description 69
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 72
- 239000000341 volatile oil Substances 0.000 claims description 65
- 239000003814 drug Substances 0.000 claims description 63
- 239000000284 extract Substances 0.000 claims description 24
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- KUFXJZXMWHNCEH-UHFFFAOYSA-N cyperone Chemical class C1CC(=O)C(C)=C2CC(C(=C)C)CCC21C KUFXJZXMWHNCEH-UHFFFAOYSA-N 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 18
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical class C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 235000012424 soybean oil Nutrition 0.000 claims description 10
- 239000003549 soybean oil Substances 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 9
- 235000019198 oils Nutrition 0.000 claims description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000002274 desiccant Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 238000006356 dehydrogenation reaction Methods 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 239000010775 animal oil Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 28
- 230000008569 process Effects 0.000 abstract description 8
- 244000075634 Cyperus rotundus Species 0.000 abstract description 2
- 235000016854 Cyperus rotundus Nutrition 0.000 abstract description 2
- 241000244365 Ligusticum sinense Species 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 18
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 14
- -1 ligustilide compound Chemical class 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- KUFXJZXMWHNCEH-DOMZBBRYSA-N (4as,7r)-1,4a-dimethyl-7-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one Chemical compound C1CC(=O)C(C)=C2C[C@H](C(=C)C)CC[C@]21C KUFXJZXMWHNCEH-DOMZBBRYSA-N 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 229940090044 injection Drugs 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 239000013558 reference substance Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000007901 soft capsule Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- RTBLDXVIGWSICW-JMSVASOKSA-N (1R,7R,10R)-4,10,11,11-tetramethyltricyclo[5.3.1.01,5]undec-4-ene Chemical compound C[C@@H]1CC[C@@H]2CC3=C(C)CC[C@]13C2(C)C RTBLDXVIGWSICW-JMSVASOKSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 5
- 101800000989 Oxytocin Proteins 0.000 description 5
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229960000935 dehydrated alcohol Drugs 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 5
- 229960001723 oxytocin Drugs 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- NVEQFIOZRFFVFW-RGCMKSIDSA-N caryophyllene oxide Chemical compound C=C1CC[C@H]2O[C@]2(C)CC[C@H]2C(C)(C)C[C@@H]21 NVEQFIOZRFFVFW-RGCMKSIDSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 239000010692 aromatic oil Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PDSNLYSELAIEBU-GUIRCDHDSA-N (+)-longifolene Chemical compound C1CCC(C)(C)[C@H]2[C@@H]3CC[C@H]2[C@@]1(C)C3=C PDSNLYSELAIEBU-GUIRCDHDSA-N 0.000 description 2
- ITYNGVSTWVVPIC-DHGKCCLASA-N (-)-allo-Aromadendrene Chemical compound C([C@@H]1[C@H]2C1(C)C)CC(=C)[C@@H]1[C@H]2[C@H](C)CC1 ITYNGVSTWVVPIC-DHGKCCLASA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- VEGYMPQCXPVQJY-UHFFFAOYSA-N (10ξ)-eudesma-4,6-diene Chemical compound C1CCC2(C)CCC(C(C)C)=CC2=C1C VEGYMPQCXPVQJY-UHFFFAOYSA-N 0.000 description 2
- GIBQERSGRNPMEH-RYUDHWBXSA-N (1s,4s)-1,4-dimethyl-7-propan-2-ylidene-2,3,4,5,6,8-hexahydro-1h-azulene Chemical compound C1([C@H](CCC(C2)=C(C)C)C)=C2[C@@H](C)CC1 GIBQERSGRNPMEH-RYUDHWBXSA-N 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 2
- KITKOMRVEUKLLD-UHFFFAOYSA-N 1h-cyclopropa[e]azulene Chemical compound C1=CC2=CC=CC2=C2CC2=C1 KITKOMRVEUKLLD-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 244000166124 Eucalyptus globulus Species 0.000 description 2
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241000053227 Themus Species 0.000 description 2
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- UIDUJXXQMGYOIN-UHFFFAOYSA-N aromadendrin Natural products CC1(C)C2C1CCC(C)C1C2C(C)CC1 UIDUJXXQMGYOIN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- OCKPCBLVNKHBMX-UHFFFAOYSA-N butylbenzene Chemical compound CCCCC1=CC=CC=C1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 150000001993 dienes Chemical class 0.000 description 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
- 229960000452 diethylstilbestrol Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- XNOPRXBHLZRZKH-MQYCRUOZSA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1C(CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-MQYCRUOZSA-N 0.000 description 2
- 229940082408 oxytocin injection Drugs 0.000 description 2
- JAWSHISYWRRQQQ-HFAKWTLXSA-N patchoulenone Chemical compound C[C@@H]1CC[C@@H]2C(=O)C3=C(C)CC[C@]13C2(C)C JAWSHISYWRRQQQ-HFAKWTLXSA-N 0.000 description 2
- KFUCYPGCMLPUMT-UHFFFAOYSA-N perlolyrine Chemical compound O1C(CO)=CC=C1C1=NC=CC2=C1NC1=CC=CC=C21 KFUCYPGCMLPUMT-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- WXQGPFZDVCRBME-QEJZJMRPSA-N (-)-thujopsene Chemical compound C([C@@]1(C)CC=C2C)CCC(C)(C)[C@]11[C@H]2C1 WXQGPFZDVCRBME-QEJZJMRPSA-N 0.000 description 1
- NUIFDRMJKLJEJE-HNNXBMFYSA-N (4aS)-1,4a-dimethyl-7-propan-2-yl-3,4,5,6-tetrahydronaphthalen-2-one Chemical compound O=C1CC[C@]2(C)CCC(C(C)C)=CC2=C1C NUIFDRMJKLJEJE-HNNXBMFYSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 241001290610 Abildgaardia Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- ATWHGWYKSFRYBN-UHFFFAOYSA-N Amygdaloside Natural products O1C(=O)C2(C)CCCC(C3CC4)(C)C2C1OCC3(C1)CC4C1(O)COC1OC(CO)C(O)C(O)C1O ATWHGWYKSFRYBN-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- APWLDLGOYJHNIK-YUELXQCFSA-N Cyperol Chemical compound C1C[C@@H](O)C(C)=C2C[C@H](C(=C)C)CC[C@]21C APWLDLGOYJHNIK-YUELXQCFSA-N 0.000 description 1
- APWLDLGOYJHNIK-CFVMTHIKSA-N Cyperol Natural products O[C@H]1C(C)=C2[C@](C)(CC1)CC[C@H](C(=C)C)C2 APWLDLGOYJHNIK-CFVMTHIKSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000002513 Flank pain Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- CBSRFDQDBGGSEA-UHFFFAOYSA-N Selinene Natural products CC(=C1CCC2(C)CCCC(=C)C2(C)C1)C CBSRFDQDBGGSEA-UHFFFAOYSA-N 0.000 description 1
- 244000296102 Selinum monnieri Species 0.000 description 1
- 235000019084 Selinum monnieri Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229940060585 alora Drugs 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- NUIFDRMJKLJEJE-UHFFFAOYSA-N beta-cyperone Natural products O=C1CCC2(C)CCC(C(C)C)=CC2=C1C NUIFDRMJKLJEJE-UHFFFAOYSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- LLVUBGQEALYPBE-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1.C1CCC=CC1 LLVUBGQEALYPBE-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940085071 diethylstilbestrol 1 mg Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- CSKINCSXMLCMAR-ZETOZRRWSA-N patchoulene Chemical compound C1[C@@H](C2(C)C)CC[C@@]2(C)C2=C1[C@H](C)CC2 CSKINCSXMLCMAR-ZETOZRRWSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- VPQBJIRQUUEAFC-UHFFFAOYSA-N selinene Natural products C1CC=C(C)C2CC(C(C)C)CCC21C VPQBJIRQUUEAFC-UHFFFAOYSA-N 0.000 description 1
- 150000003598 selinene derivatives Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- WXQGPFZDVCRBME-UHFFFAOYSA-N thujopsene Natural products CC1=CCC2(C)CCCC(C)(C)C22C1C2 WXQGPFZDVCRBME-UHFFFAOYSA-N 0.000 description 1
- 239000008853 tianma gouteng Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- RBNWAMSGVWEHFP-UHFFFAOYSA-N trans-p-Menthane-1,8-diol Chemical compound CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
试验方法 | 萃取率(%) | 总藁苯内酯类化合物含量 | α-香附酮含量 |
本发明 | 3.3 | 93.5(mg/ml) | 62.4(mg/ml) |
CN1352980A | 2.4 | 75.2(mg/ml) | 43.9(mg/ml) |
编号 | R<sub>t</sub>(min) | 分子式 | 分子量 | 挥发油A | 挥发油B |
0 | 10.80 | C<sub>12</sub>H<sub>20</sub>O<sub>2</sub> | 196 | 醋酸萜品醇 | / |
1 | 11.35 | C<sub>15</sub>H<sub>22</sub> | 202 | 环异长松叶烯 | 环异长松叶烯 |
2 | 11.66 | C<sub>15</sub>H<sub>22</sub> | 202 | 香橙烯 | 香橙烯 |
3 | 11.78 | C<sub>15</sub>H<sub>24</sub> | 204 | 烯 | 烯 |
4 | 12.39 | C<sub>15</sub>H<sub>24</sub> | 204 | δ-芹子烯 | / |
5 | 12.42 | C<sub>15</sub>H<sub>24</sub> | 204 | / | 亚甲基 |
6 | 13.50 | C<sub>15</sub>H<sub>24</sub> | 204 | 1H-Cycloprop[e]azulene | 1H-Cycloprop[e]azulene |
7 | 13.78 | C<sub>12</sub>H<sub>18</sub> | 162 | 环已烯 | 环已烯 |
8 | 14.12 | C<sub>17</sub>H<sub>26</sub>O<sub>2</sub> | 262 | Bicylo[4.4.0]dec-6-en-9.beta-ol | Bicylo[4.4.0]dec-6-en-9.beta-ol |
9 | 14.53 | C<sub>15</sub>H<sub>24</sub> | 204 | 桉叶二烯 | 桉叶二烯 |
10 | 14.78 | C<sub>15</sub>H<sub>24</sub> | 204 | 广藿香烯 | / |
11 | 14.79 | C<sub>15</sub>H<sub>24</sub> | 204 | / | 1,2,3,4,4a,5,6,8a-octahydro-4a,8-dimethyl-2-(l-methyletheyl)- |
12 | 15.27 | C<sub>15</sub>H<sub>24</sub> | 204 | / | β-愈创木烯 |
13 | 15.63 | C<sub>15</sub>H<sub>24</sub> | 204 | 罗汉柏烯 | / |
14 | 15.44 | C<sub>15</sub>H<sub>24</sub> | 204 | / | α-长松叶烯 |
15 | 15.91 | C<sub>12</sub>H<sub>16</sub>O<sub>3</sub> | 208 | 1.2.3-trimethoxy-5-(2-propenyl) | / |
16 | 16.09 | C<sub>15</sub>H<sub>22</sub>O | 218 | 4.6.6-Trimethl-2-(3-methylbuta-1.3-dienyl)-3-0xatricyclo[5.1.0.0(2.4)]octane | 4.6.6-Trimethl-2-(3-methylbuta-1.3-dienyl)-3-0xatricyclo[5.1.0.0(2.4)]octane |
17 | 17.08 | C<sub>15</sub>H<sub>24</sub>O | 220 | 氧化丁香烯 | 氧化丁香烯 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810151194XA CN101375983B (zh) | 2008-09-28 | 2008-09-28 | 一种用于治疗痛经的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810151194XA CN101375983B (zh) | 2008-09-28 | 2008-09-28 | 一种用于治疗痛经的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101375983A CN101375983A (zh) | 2009-03-04 |
CN101375983B true CN101375983B (zh) | 2010-12-08 |
Family
ID=40419829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810151194XA Active CN101375983B (zh) | 2008-09-28 | 2008-09-28 | 一种用于治疗痛经的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101375983B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102205025B (zh) * | 2011-05-06 | 2012-11-07 | 烟台渤海制药集团有限公司 | 一种治疗痛经和月经不调的中药制剂的制备方法 |
CN104155399B (zh) * | 2014-08-22 | 2016-03-09 | 江西中医药大学 | 一种四制香附饮片的质量控制方法 |
CN104524085A (zh) * | 2014-12-08 | 2015-04-22 | 王淑英 | 一种用于治疗原发性痛经的药物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1352980A (zh) * | 2001-11-30 | 2002-06-12 | 广州中医药大学科技产业园有限公司 | 治疗偏头痛的药物及其制备方法 |
CN1546088A (zh) * | 2003-12-02 | 2004-11-17 | 胡惠平 | 一种治疗妇女痛经的中药制剂 |
-
2008
- 2008-09-28 CN CN200810151194XA patent/CN101375983B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1352980A (zh) * | 2001-11-30 | 2002-06-12 | 广州中医药大学科技产业园有限公司 | 治疗偏头痛的药物及其制备方法 |
CN1546088A (zh) * | 2003-12-02 | 2004-11-17 | 胡惠平 | 一种治疗妇女痛经的中药制剂 |
Non-Patent Citations (2)
Title |
---|
刘庆林.川芎药对的临床应用解析.《中医药学刊》.2004,第22卷(第9期),第1730至1731页. * |
刘庆林.香附药对的临床应用举隅.《湖南中医药导报》.2002,第8卷(第11期),第642至643,653页. * |
Also Published As
Publication number | Publication date |
---|---|
CN101375983A (zh) | 2009-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Radix Puerariae: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use | |
CN101590134B (zh) | 具有抗炎镇痛作用的地榆总三萜及其制备方法 | |
CN101214278A (zh) | 提取五味子总木脂素的新原料及制备工艺和用途 | |
CN101700300B (zh) | 治疗胃肠功能紊乱或肠易激综合症的中药挥发油组合物、其制备方法及在制备药物中的应用 | |
CN1321679C (zh) | 治疗心血管病的姜、陈皮提取物的混合物 | |
CN101978987B (zh) | 一种冬凌草提取物在制备治疗抗脑缺血药物中的应用 | |
CN101375983B (zh) | 一种用于治疗痛经的中药组合物及其制备方法 | |
Wang et al. | Amelioration of chronic prostatitis by fractions of Mongolian medicine Hosta plantaginea flowers via inhibition of NF-κB, MAPKs, JAK-STAT, and PI3K-Akt signaling pathways in rats | |
CN102258742B (zh) | 一种治疗抑郁症的中药组合物及其制备方法 | |
CN103721148B (zh) | 一种治疗急慢性胃肠炎的益智仁组合物及其制备方法 | |
CN108434399A (zh) | 一种防治肿瘤的中药组合物及制备方法 | |
CN1327859C (zh) | 五味子提取物,其制备方法及其用途 | |
CN103211858B (zh) | 一种四君子滴丸制剂 | |
CN101310758A (zh) | 一种抗抑郁复方中药及其制备方法 | |
CN101007044A (zh) | 一种治疗溃疡病的药物组合物及其制备方法和用途 | |
CN107266464B (zh) | 一种泽泻汤提取物及其应用 | |
CN104435293B (zh) | 异型南五味子总三萜乙醇提取物在制备抗关节炎药物中的应用 | |
CN103550237A (zh) | 一种茜草活性成分组合物及其在医药上的应用 | |
CN1579485B (zh) | 治疗肠功能紊乱的中药组合物及其制备方法 | |
CN101766676B (zh) | 一种楹树提取物、其制备方法及其组合物与用途 | |
CN103083408B (zh) | 一种中药提取物组合物、其制备方法及其用途 | |
CN101380356B (zh) | 藏药独一味总黄酮提取物及其提取方法和用途 | |
CN101816702B (zh) | 取自夏枯草的防治肺癌组合物及其在制备防治肺癌药物中的应用 | |
CN100377723C (zh) | 首乌苷粗提物及其在制备治疗脂肪肝药物中的应用 | |
CN103893676B (zh) | 一种治疗原发性痛经的中药组合物的制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Xi'an Xintong Pharmaceutical Research Co., Ltd. Assignor: Zhang Dengke Contract record no.: 2011610000058 Denomination of invention: Chinese medicine compound for curing dysmenorrheal and preparation method thereof Granted publication date: 20101208 License type: Exclusive License Open date: 20090304 Record date: 20110629 |
|
ASS | Succession or assignment of patent right |
Owner name: XI'AN XINTONG MEDICINE RESEARCH CO., LTD. Free format text: FORMER OWNER: ZHANG DENGKE Effective date: 20111009 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20111009 Address after: 710077 C, block 2, room 69, pioneer research and Development Park, 205 Kam Yip Road, hi tech Zone, Shaanxi, Xi'an Patentee after: Xi'an Xintong Pharmaceutical Research Co., Ltd. Address before: 710077, block C, No. 69, Kam Yip Road, Xi'an hi tech Zone, Shaanxi, two Patentee before: Zhang Dengke |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190708 Address after: 274039 No. 1668 Zhonghua West Road, Heze City, Shandong Province Patentee after: Shandong Buchang Shenzhou Pharmaceuticals Co., Ltd. Address before: 710077 Room 205, 2nd Floor, Block C, Venture Development Park, 69 Jinye Road, Xi'an High-tech Zone, Shaanxi Province Patentee before: Xi'an Xintong Pharmaceutical Research Co., Ltd. |